Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Gold: Rally stalls as Fed outlook stays hawkish – Commerzbank

Gold: Rally stalls as Fed outlook stays hawkish – Commerzbank

FXStreetFXStreet2026/07/17 15:00
By:FXStreet

Thu Lan Nguyen at Commerzbank notes that weaker United States (US inflation data briefly supported Gold, but the price has slipped back below USD 4,000 per troy ounce. With markets still pricing at least one Federal Reserve rate hike and energy-price risks from the Middle East conflict, she sees limited near-term upside, though a more dovish Fed stance could later re-ignite the Gold rally.

Limited upside unless Fed shifts

"Weaker US inflation data — both consumer and producer prices surprised with slower growth in June — have dampened expectations for US interest rate hikes. While the market had previously priced in nearly two rate hikes by year-end, only a single 25-basis-point rate hike is now fully priced in. However, this provided only a brief boost to the gold price. Yesterday, it slipped back below the USD 4,000 per troy ounce mark, where it is currently trading."

"In the short term, further upside potential is likely to remain limited. With the ongoing escalation of the Middle East conflict and the resulting risk of another sharp spike in energy prices, expectations of interest rate hikes are likely to persist for some time."

"A correction, regardless of developments in the US-Iran conflict, is likely to occur only if the market's assessment of the Federal Reserve were to fundamentally change."

"But the picture could also shift again: Warsh, for example, is already suggesting that AI would boost productivity and therefore likely have an inflation-dampening effect. New York Fed President John Williams also recently made similar comments, referring to a long-term downward trend in inflation."

"If this view gains traction within the FOMC, it could mean that interest rate hikes are not considered necessary to combat current inflation."

"The price of gold would then likely benefit not only in the short term from the market pricing out interest rate hikes, but also from the fact that the market perceives increased inflation risks in the long term due to a significantly more dovish stance by the Federal Reserve."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26